Barclays Maintains Overweight on Solid Biosciences, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Overweight rating on Solid Biosciences (NASDAQ:SLDB) but lowers the price target from $18 to $15.
August 14, 2024 | 2:40 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays analyst Gena Wang maintains an Overweight rating on Solid Biosciences but lowers the price target from $18 to $15.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some concerns or adjustments in expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100